Morgan Stanley’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-620,001
| Closed | -$2.54M | – | 8278 |
|
|
2022
Q1 | $2.54M | Sell |
620,001
-21,652
| -3% | -$78.5K | ﹤0.01% | 4341 |
|
|
2021
Q4 | $2.29M | Sell |
641,653
-385,874
| -38% | -$1.35M | ﹤0.01% | 4471 |
|
|
2021
Q3 | $3.74M | Sell |
1,027,527
-589,577
| -36% | -$2.38M | ﹤0.01% | 4021 |
|
|
2021
Q2 | $7.05M | Sell |
1,617,104
-4,395
| -0.3% | -$17.9K | ﹤0.01% | 3411 |
|
|
2021
Q1 | $6.67M | Buy |
1,621,499
+996,992
| +160% | +$4.32M | ﹤0.01% | 3102 |
|
|
2020
Q4 | $2.49M | Buy |
624,507
+391,570
| +168% | +$1.27M | ﹤0.01% | 3961 |
|
|
2020
Q3 | $629K | Sell |
232,937
-37,837
| -14% | -$105K | ﹤0.01% | 4523 |
|
|
2020
Q2 | $745K | Sell |
270,774
-916,897
| -77% | -$2.56M | ﹤0.01% | 4378 |
|
|
2020
Q1 | $2.8M | Sell |
1,187,671
-213,708
| -15% | -$727K | ﹤0.01% | 3044 |
|
|
2019
Q4 | $6.59M | Buy |
1,401,379
+487,466
| +53% | +$1.99M | ﹤0.01% | 2883 |
|
|
2019
Q3 | $3.06M | Sell |
913,913
-53,607
| -6% | -$177K | ﹤0.01% | 3402 |
|
|
2019
Q2 | $3.18M | Sell |
967,520
-1,163,312
| -55% | -$3.37M | ﹤0.01% | 3374 |
|
|
2019
Q1 | $6.46M | Buy |
2,130,832
+1,314,002
| +161% | +$4.26M | ﹤0.01% | 2461 |
|
|
2018
Q4 | $2.22M | Buy |
816,830
+55,960
| +7% | +$184K | ﹤0.01% | 3681 |
|
|
2018
Q3 | $2.56M | Buy |
760,870
+112,221
| +17% | +$347K | ﹤0.01% | 3803 |
|
|
2018
Q2 | $1.67M | Sell |
648,649
-16,087
| -2% | -$40K | ﹤0.01% | 4243 |
|
|
2018
Q1 | $1.46M | Sell |
664,736
-128,862
| -16% | -$290K | ﹤0.01% | 4265 |
|
|
2017
Q4 | $1.58M | Sell |
793,598
-36,711
| -4% | -$79.9K | ﹤0.01% | 4222 |
|
|
2017
Q3 | $2.69M | Buy |
830,309
+291,385
| +54% | +$899K | ﹤0.01% | 3585 |
|
|
2017
Q2 | $1.74M | Sell |
538,924
-457,189
| -46% | -$1.3M | ﹤0.01% | 3925 |
|
|
2017
Q1 | $2.83M | Buy |
996,113
+602,834
| +153% | +$1.45M | ﹤0.01% | 3488 |
|
|
2016
Q4 | $917K | Buy |
393,279
+371,684
| +1,721% | +$708K | ﹤0.01% | 4535 |
|
|
2016
Q3 | $37K | Sell |
21,595
-64,169
| -75% | -$78.6K | ﹤0.01% | 5705 |
|
|
2016
Q2 | $90K | Sell |
85,764
-2,561,723
| -97% | -$2.47M | ﹤0.01% | 5285 |
|
|
2016
Q1 | $2.3M | Buy |
2,647,487
+2,553,715
| +2,723% | +$2.47M | ﹤0.01% | 3234 |
|
|
2015
Q4 | $114K | Buy |
93,772
+63,376
| +209% | +$88.2K | ﹤0.01% | 5336 |
|
|
2015
Q3 | $52K | Sell |
30,396
-328,535
| -92% | -$644K | ﹤0.01% | 5715 |
|
|
2015
Q2 | $746K | Buy |
358,931
+336,729
| +1,517% | +$817K | ﹤0.01% | 4417 |
|
|
2015
Q1 | $59K | Sell |
22,202
-52,916
| -70% | -$134K | ﹤0.01% | 5735 |
|
|
2014
Q4 | $192K | Buy |
75,118
+65,023
| +644% | +$146K | ﹤0.01% | 5259 |
|
|
2014
Q3 | $19K | Sell |
10,095
-15,311
| -60% | -$33.4K | ﹤0.01% | 6027 |
|
|
2014
Q2 | $68K | Buy |
25,406
+8,198
| +48% | +$24.7K | ﹤0.01% | 5655 |
|
|
2014
Q1 | $60K | Buy |
17,208
+1,111
| +7% | +$4.93K | ﹤0.01% | 5644 |
|
|
2013
Q4 | $71K | Sell |
16,097
-76,352
| -83% | -$311K | ﹤0.01% | 5477 |
|
|
2013
Q3 | $375K | Buy |
92,449
+37,997
| +70% | +$166K | ﹤0.01% | 4523 |
|
|
2013
Q2 | $227K | Buy |
+54,452
| New | +$210K | ﹤0.01% | 4768 |
|
Other funds holding ATRS
Morgan Stanley's ATRS Position: Q2 2022 in Review
Morgan Stanley sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 620,001 shares — an estimated $2.54M sold.
Morgan Stanley first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $7.05M in Q2 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Morgan Stanley reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Morgan Stanley sold 620,001 Antares Pharma, Inc. shares in Q2 2022, an estimated $2.54M.
- Morgan Stanley first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Morgan Stanley's Antares Pharma, Inc. position peaked at $7.05M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.